Cost-minimization analysis of intravenous adenosine and dipyridamole in thallous chloride TI 201 SPECT myocardial perfusion imaging

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: To conduct a cost-minimization analysis of intravenous adenosine and intravenous dipyridamole in thallous chloride TI 201 single- photon emission computed tomography (SPECT) myocardial perfusion imaging. DESIGN: A retrospective, open-label, cost-minimization analysis. SETTING: University hospital, outpatient nuclear medicine department. PATIENTS: Eighty-three patients undergoing dipyridamole TI 201 SPECT and 166 patients undergoing adenosine TI 201 SPECT. MAIN OUTCOME MEASURES: A cost- minimization analysis was conducted using a direct cost accounting approach estimating institutional costs. For the purpose of this study, sensitivity and specificity between adenosine SPECT and dipyridamole SPECT were assumed to be identical. Key costs evaluated included acquisition, administration, monitoring, treatment of adverse effects, follow-up care, and repeat tests. RESULTS: Adenosine increased heart rate and lowered blood pressure to a significantly greater extent than dipyridamole. The frequency of adverse reactions was not significantly different (p = 0.103) between adenosine (1.64 ± 1.32 per patient) and dipyridamole (1.36 ± 1.23 per patient). The frequency of prolonged and late-onset adverse effects was significantly greater for dipyridamole than for adenosine (p <0.001). The frequency of adverse events requiting medical intervention was statistically greater for dipyridamole (24%) compared with adenosine (5%) (p <0.00001). Total cost was significantly less for adenosine ($378.50 ± $128.20 per patient) compared with dipyridamole ($485.60 ± $230.40). Although adenosine had a significantly greater acquisition cost than dipyridamole (p <0.0001), administration, monitoring, and adverse reaction costs were significantly less for adenosine than for dipyridamole. CONCLUSIONS: The cost of using dipyridamole is significantly greater than the cost of using adenosine despite adenosine's high acquisition cost. Adenosine is less expensive to use because of lower administration costs, monitoring costs, and adverse effect costs. Adenosine should be the agent of choice for pharmacologic vasodilation in the setting of myocardial perfusion imaging.

Original languageEnglish
Pages (from-to)974-979
Number of pages6
JournalAnnals of Pharmacotherapy
Volume31
Issue number9
StatePublished - Sep 1997

Fingerprint

Myocardial Perfusion Imaging
Dipyridamole
Single-Photon Emission-Computed Tomography
Adenosine
Costs and Cost Analysis
thallium chloride
Hospital Nuclear Medicine Departments
Aftercare
Vasodilation

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{39f938e0d6604de293a0aeeff9a39773,
title = "Cost-minimization analysis of intravenous adenosine and dipyridamole in thallous chloride TI 201 SPECT myocardial perfusion imaging",
abstract = "OBJECTIVE: To conduct a cost-minimization analysis of intravenous adenosine and intravenous dipyridamole in thallous chloride TI 201 single- photon emission computed tomography (SPECT) myocardial perfusion imaging. DESIGN: A retrospective, open-label, cost-minimization analysis. SETTING: University hospital, outpatient nuclear medicine department. PATIENTS: Eighty-three patients undergoing dipyridamole TI 201 SPECT and 166 patients undergoing adenosine TI 201 SPECT. MAIN OUTCOME MEASURES: A cost- minimization analysis was conducted using a direct cost accounting approach estimating institutional costs. For the purpose of this study, sensitivity and specificity between adenosine SPECT and dipyridamole SPECT were assumed to be identical. Key costs evaluated included acquisition, administration, monitoring, treatment of adverse effects, follow-up care, and repeat tests. RESULTS: Adenosine increased heart rate and lowered blood pressure to a significantly greater extent than dipyridamole. The frequency of adverse reactions was not significantly different (p = 0.103) between adenosine (1.64 ± 1.32 per patient) and dipyridamole (1.36 ± 1.23 per patient). The frequency of prolonged and late-onset adverse effects was significantly greater for dipyridamole than for adenosine (p <0.001). The frequency of adverse events requiting medical intervention was statistically greater for dipyridamole (24{\%}) compared with adenosine (5{\%}) (p <0.00001). Total cost was significantly less for adenosine ($378.50 ± $128.20 per patient) compared with dipyridamole ($485.60 ± $230.40). Although adenosine had a significantly greater acquisition cost than dipyridamole (p <0.0001), administration, monitoring, and adverse reaction costs were significantly less for adenosine than for dipyridamole. CONCLUSIONS: The cost of using dipyridamole is significantly greater than the cost of using adenosine despite adenosine's high acquisition cost. Adenosine is less expensive to use because of lower administration costs, monitoring costs, and adverse effect costs. Adenosine should be the agent of choice for pharmacologic vasodilation in the setting of myocardial perfusion imaging.",
author = "Hilleman, {Daniel E.} and Lucas, {B. Daniel} and Mohiuddin, {Syed M.} and Holmberg, {Mark Jeffrey}",
year = "1997",
month = "9",
language = "English",
volume = "31",
pages = "974--979",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Cost-minimization analysis of intravenous adenosine and dipyridamole in thallous chloride TI 201 SPECT myocardial perfusion imaging

AU - Hilleman, Daniel E.

AU - Lucas, B. Daniel

AU - Mohiuddin, Syed M.

AU - Holmberg, Mark Jeffrey

PY - 1997/9

Y1 - 1997/9

N2 - OBJECTIVE: To conduct a cost-minimization analysis of intravenous adenosine and intravenous dipyridamole in thallous chloride TI 201 single- photon emission computed tomography (SPECT) myocardial perfusion imaging. DESIGN: A retrospective, open-label, cost-minimization analysis. SETTING: University hospital, outpatient nuclear medicine department. PATIENTS: Eighty-three patients undergoing dipyridamole TI 201 SPECT and 166 patients undergoing adenosine TI 201 SPECT. MAIN OUTCOME MEASURES: A cost- minimization analysis was conducted using a direct cost accounting approach estimating institutional costs. For the purpose of this study, sensitivity and specificity between adenosine SPECT and dipyridamole SPECT were assumed to be identical. Key costs evaluated included acquisition, administration, monitoring, treatment of adverse effects, follow-up care, and repeat tests. RESULTS: Adenosine increased heart rate and lowered blood pressure to a significantly greater extent than dipyridamole. The frequency of adverse reactions was not significantly different (p = 0.103) between adenosine (1.64 ± 1.32 per patient) and dipyridamole (1.36 ± 1.23 per patient). The frequency of prolonged and late-onset adverse effects was significantly greater for dipyridamole than for adenosine (p <0.001). The frequency of adverse events requiting medical intervention was statistically greater for dipyridamole (24%) compared with adenosine (5%) (p <0.00001). Total cost was significantly less for adenosine ($378.50 ± $128.20 per patient) compared with dipyridamole ($485.60 ± $230.40). Although adenosine had a significantly greater acquisition cost than dipyridamole (p <0.0001), administration, monitoring, and adverse reaction costs were significantly less for adenosine than for dipyridamole. CONCLUSIONS: The cost of using dipyridamole is significantly greater than the cost of using adenosine despite adenosine's high acquisition cost. Adenosine is less expensive to use because of lower administration costs, monitoring costs, and adverse effect costs. Adenosine should be the agent of choice for pharmacologic vasodilation in the setting of myocardial perfusion imaging.

AB - OBJECTIVE: To conduct a cost-minimization analysis of intravenous adenosine and intravenous dipyridamole in thallous chloride TI 201 single- photon emission computed tomography (SPECT) myocardial perfusion imaging. DESIGN: A retrospective, open-label, cost-minimization analysis. SETTING: University hospital, outpatient nuclear medicine department. PATIENTS: Eighty-three patients undergoing dipyridamole TI 201 SPECT and 166 patients undergoing adenosine TI 201 SPECT. MAIN OUTCOME MEASURES: A cost- minimization analysis was conducted using a direct cost accounting approach estimating institutional costs. For the purpose of this study, sensitivity and specificity between adenosine SPECT and dipyridamole SPECT were assumed to be identical. Key costs evaluated included acquisition, administration, monitoring, treatment of adverse effects, follow-up care, and repeat tests. RESULTS: Adenosine increased heart rate and lowered blood pressure to a significantly greater extent than dipyridamole. The frequency of adverse reactions was not significantly different (p = 0.103) between adenosine (1.64 ± 1.32 per patient) and dipyridamole (1.36 ± 1.23 per patient). The frequency of prolonged and late-onset adverse effects was significantly greater for dipyridamole than for adenosine (p <0.001). The frequency of adverse events requiting medical intervention was statistically greater for dipyridamole (24%) compared with adenosine (5%) (p <0.00001). Total cost was significantly less for adenosine ($378.50 ± $128.20 per patient) compared with dipyridamole ($485.60 ± $230.40). Although adenosine had a significantly greater acquisition cost than dipyridamole (p <0.0001), administration, monitoring, and adverse reaction costs were significantly less for adenosine than for dipyridamole. CONCLUSIONS: The cost of using dipyridamole is significantly greater than the cost of using adenosine despite adenosine's high acquisition cost. Adenosine is less expensive to use because of lower administration costs, monitoring costs, and adverse effect costs. Adenosine should be the agent of choice for pharmacologic vasodilation in the setting of myocardial perfusion imaging.

UR - http://www.scopus.com/inward/record.url?scp=0030799444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030799444&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 974

EP - 979

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -